AI Article Synopsis
- HBeAg is an important marker for evaluating hepatitis B virus replication and its reliability in testing was assessed using standard methods and clinical samples.
- Performance analyses of several enzyme immunoassays showed significant differences in their sensitivity and antibody affinity.
- The variations in antibody affinity may affect the accuracy and reliability of HBeAg tests used for diagnosing and managing hepatitis B.
Article Abstract
Hepatitis B virus-e-antigen (HBeAg) is a viral marker to assess hepatitis B virus (HBV) replication. We have evaluated the reliability of three commonly available HBeAg immunoassays using World Health Organization-International Standard and clinical samples. In addition the performance of enzyme immunoassays (EIAs) was assessed by kinetic binding and reagent exchange experiments. Analytical and diagnostic sensitivity were significantly different among HBeAg assays (P < 0.01). The affinity of capture/detector antibodies varied significantly between EIAs (P < 0.01). Our findings suggest that significant difference in the affinity of capture/detector antibodies to HBeAg may impact the overall performance and the reliability of currently available HBeAg assays in HBV diagnosis and management.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/15321819.2018.1529680 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
RNA Sequencing Analysis of Patients with Chronic Hepatitis B Treated Using PEGylated Interferon.
Int J Gen Med
October 2024
Department of Infectious Disease Control and Prevention, Yueqing Center for Disease Control and Prevention, Wenzhou, 325600, People's Republic of China.
Purpose: Worldwide, chronic hepatitis B virus (CHB) infection is a public health concern, ultimately leading to liver cirrhosis and hepatocellular carcinoma. Currently, patients with CHB can be treated using polyethylene glycol (PEG)ylated interferon (PEG-IFN) antiviral therapy, which has both immune modulatory and antiviral properties. This study aimed to reveal the mechanism underlying the effect of PEG-IFN therapy, to rationally optimize this therapeutic option.
View Article and Find Full Text PDFUp-regulation of MDSCs accumulation and Th2 biased response to co-stimulation of CsESP from Clonorchis sinensis and HBeAg in vitro.
Acta Trop
December 2024
Department of Parasitology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou 510080, Guangdong, PR China; Key Laboratory for Tropical Diseases Control, Ministry of Education, Sun Yat-Sen University, Guangzhou 510080, Guangdong, PR China; Provincial Engineering Technology Research Center for Diseases-vectors Control, Guangzhou 510080, Guangdong, PR China. Electronic address:
Co-infection with Clonorchis sinensis (C. sinensis) and Hepatitis B virus (HBV) are commonly observed in endemic areas of Clonorchiasis. Chronic infection of C.
View Article and Find Full Text PDFEffect of nucleos(t)ide analogue discontinuation on the prognosis of HBeAg-negative hepatitis B virus-related hepatocellular carcinoma after hepatectomy: A propensity score matching analysis.
Cancer Med
August 2024
Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, P. R. China.
Background: Although nucleos(t)ide analogues (NAs) are thought to reduce the risk of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), the effect of NA discontinuation on the prognosis of HBV-related HCC after hepatectomy is rarely reported. We aimed to investigate the potential for hepatitis B virus e antigen (HBeAg)-negative HBV-related HCC patients to discontinue NAs based on preoperative hepatitis B virus surface antigen (HBsAg) status.
Methods: This historical cohort study involved 1232 NA-treated HBeAg-negative patients who underwent curative hepatectomy for HBV-related HCC from 2014 to 2019.
[Study on mechanism of Chinese Yam polysaccharide synergizing nucleoside analogues against hepatitis B virus through p38 MAPK signaling pathway].
Zhongguo Zhong Yao Za Zhi
May 2024
Department of Gastroenterology, the 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army Lanzhou 730050, China.
Article Synopsis
- This study investigates how Chinese Yam polysaccharides work alongside nucleoside analogues (NAs) to combat hepatitis B virus (HBV) resistance in liver cells.
- Researchers tested different concentrations of Chinese Yam polysaccharides and a drug called entecavir on HepG2.2.15 cells to find the most effective dosage and treatment duration.
- Results showed that both treatments individually and in combination significantly reduced HBV markers (HBsAg and HBeAg) and HBV-DNA levels, with the combination being particularly effective, while also affecting the p38 MAPK signaling pathway and related protein expressions.
Hepatitis B virus e antigen induces atypical metabolism and differentially regulates programmed cell deaths of macrophages.
PLoS Pathog
March 2024
Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America.
Macrophages can undergo M1-like proinflammatory polarization with low oxidative phosphorylation (OXPHOS) and high glycolytic activities or M2-like anti-inflammatory polarization with the opposite metabolic activities. Here we show that M1-like macrophages induced by hepatitis B virus (HBV) display high OXPHOS and low glycolytic activities. This atypical metabolism induced by HBV attenuates the antiviral response of M1-like macrophages and is mediated by HBV e antigen (HBeAg), which induces death receptor 5 (DR5) via toll-like receptor 4 (TLR4) to induce death-associated protein 3 (DAP3).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!